Big Pharma execs usually don’t just fade away. Sometimes, they jump to the money side of the biotech business, like Chris Viehbacher and Olivier Brandicourt. Some stick with a batch of mentoring board seats. Joe Jimenez not only plans to do both, he’s also going biotech entrepreneur and starting his own play — in style.
A week ago, Jimenez and his close partner Mark Fishman, who got to know each other well during their respective time as CEO and early-stage NIBR chief at Novartis, filed papers with the SEC noting that their Aditum Bio Fund I had raised the $133,040,000 they had targeted more than a year ago. Now they’re investing in it.
“When I came out of Novartis with Mark Fishman, we saw a big opportunity,” Jimenez tells me.